SRARP (steroid receptor associated and regulated protein) is a corepressor of the androgen receptor located on chromosome 1.13 that functions as a tumor suppressor 1. The protein regulates transcriptional activity of androgen and estrogen receptors through nuclear localization and protein-protein interactions, including binding to 14-3-3 proteins 1. SRARP expression is tightly controlled by androgen receptor activity in a biphasic manner: while elevated AR activity suppresses SRARP transcription, minimal AR signaling is required to maintain baseline SRARP expression in AR-positive cancer cells 1. SRARP inactivation through deletions, epigenetic silencing, and DNA hypermethylation is common in malignancies and represents an early event in carcinogenesis 1. Loss of SRARP expression correlates with downregulation of cell viability through reduced Akt and ERK signaling, and is inversely associated with genes promoting proliferation and signal transduction 1. Clinically, SRARP inactivation strongly predicts poor cancer outcomes; DNA hypermethylation and reduced expression in both tumor and adjacent normal tissues are independent predictors of worse survival 1. These findings suggest SRARP could serve translational applications as a prognostic biomarker and potential therapeutic target in cancer.